Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2012

Akebia Spins out Aerpio to Develop Tie-2 Activators and HIF-1a Stabilizers

  • Akebia Therapeutics has spun out a new company, Aerpio Therapeutics, to continue the development of its small molecule Tie-2 activator and HIF-1α stabilizer programs for multiple diseases. The spin-out’s pipeline includes lead program, AKB-9778, a Tie-2 activator in development for the treatment of diabetic macular edema (DME), which is expected to start in a Phase IIa trial during the first half of 2012. AKB-9778 is designed to inhibit human protein tyrosine phosphatase β, a negative regulator of the Tie-2 receptor, and prevent vascular leak and abnormal blood vessel growth associated with diabetic eye disease. A first-in-man study with the candidate was initiated in November 2011.

    Aerpio’s second clinical candidate, AKB-4924, is an HIF-1α stabilizer currently in late preclinical development for the treatment of inflammatory bowel disease (IBD). An IND submission is projected for late 2012. AKB-4924 is designed to stabilize HIF-1α by inhibiting HIF prolyl hydroxylases, and in particular PHD-2.

    Akebia’s own lead candidate, AKB-6548, is an orally available hypoxia-inducible factor-prolyl hydroxylase (HIF-PF) inhibitor in development for the treatment of anemia. The drug is designed to increase natural production of erythropoietin, and cause a controlled, gradual rise in hemoglobin levels in anemia patients. A Phase IIa dose-ranging trial evaluating AKB-6548 in stage 3 and 4 chronic kidney disease patients was initiated in June 2011.

    Akebia separately confirmed drawing down a $4.1 million tranche of a previously announced $22 million Series B financing to support completion of the Phase II AKB-6548 and progress its search for the optimum partner to move into pivotal Phase III studies. 



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »